Aberrant nucleic acids generated during viral replication are the main trigger for antiviral immunity, and mutations that disrupt nucleic acid metabolism can lead to autoinflammatory disorders. Here we investigated the etiology of X-linked reticulate pigmentary disorder (XLPDR), a primary immunodeficiency with autoinflammatory features. We discovered that XLPDR is caused by an intronic mutation that disrupts the expression of POLA1, which encodes the catalytic subunit of DNA polymerase-. Unexpectedly, POLA1 deficiency resulted in increased production of type I interferons. This enzyme is necessary for the synthesis of RNA:DNA primers during DNA replication and, strikingly, we found that POLA1 is also required for the synthesis of cytosolic RNA:DNA, which directly modulates interferon activation. Together this work identifies POLA1 as a critical regulator of the type I interferon response.
A r t i c l e s Innate immunity relies on the ability of the host to detect unique molecular patterns displayed by potential pathogens. Viruses and their distinctive replication cycles can generate a variety of aberrant nucleic acids that activate innate immunological sensors, which results in the production of type I interferons. Mutations that affect genes encoding products involved in these sensing mechanisms can lead to immunodeficiency in humans [1] [2] [3] . In addition, autoinflammatory syndromes characterized by spontaneous hyperactivation of the type I interferon pathway have been linked to mutations in various genes encoding products involved in nucleic acid metabolism or signaling. The most prominent condition in this category is Aicardi-Goutières syndrome (AGS), a rare genetic disorder that affects the brain, skin and other organs [4] [5] [6] . About half of AGS cases are due to mutations in genes encoding any of the three subunits of the RNase H2 complex 7 , a nuclease with RNase activity directed at RNA:DNA hybrids that is required for the removal of misincorporated ribonucleotides or RNA primers generated during DNA replication 8 . In addition, studies of autoimmune disorders have shown that critical aspects of antiviral signaling pathways in humans can be involved in inherited susceptibility to systemic lupus erythematosus 9 .
The study of defined syndromes of altered immunological function can lead to powerful insights into the function of gene products and the specific organization of immune responses in humans. With this goal in mind, we investigated the genetic etiology of X-linked reticulate pigmentary disorder (XLPDR; OMIM accession code 301220), a rare entity characterized by both recurrent infections and sterile A r t i c l e s inflammation in various organs. So far, 7 families and 14 affected people have been reported [10] [11] [12] [13] [14] [15] [16] [17] [18] . The disease typically manifests in the first few months of life, when patients usually develop recurrent pneumonias, bronchiectasis, chronic diarrhea and failure to thrive. Diffuse skin hyperpigmentation with a distinctive reticulate pattern is universally evident by early childhood, and this is later followed in many patients by hypohidrosis, corneal inflammation and scarring, enterocolitis that resembles inflammatory bowel disease, and recurrent urethral strictures. Some of these features resemble the phenotypes associated with other mutations that affect immunological function, particularly mutations in IKBKG (which encodes an essential scaffold component of the IκB kinase complex (NEMO)), which can result in similar pigmentary changes and hypohidrosis 19 . Males with XLPDR also have a characteristic facies with frontally upswept hair and flared eyebrows. Female carriers are known to have only restricted pigmentary changes along Blaschko's lines.
Our report demonstrates that XLPDR is due to a unique hypomorphic mutation of POLA1, which encodes the catalytic subunit of DNA polymerase-α, an essential component of the DNA-replication machinery. Furthermore, our results reveal a previously unrecognized role for this replicative polymerase as a modulator of interferon activation through the generation of cytosolic RNA:DNA hybrids.
RESULTS

XLPDR is caused by an intronic mutation in POLA1
Published linkage analyses have mapped the XLPDR locus to a 4.9-Mb interval of the X chromosome. However, Sanger and exomecapture sequencing failed to identify any causal mutation 20 (data not shown). For the genetic analysis performed here, we included five of the seven known XLPDR families, as well as seven new families not previously reported (Fig. 1) . The additional probands all displayed characteristic pigmentary changes of XLPDR, and most had the distinctive facial features of the syndrome ( Supplementary Fig. 1a and data not shown). Skin biopsies from two new probands demonstrated the presence of melanophages and amyloid-like material in the upper dermis ( Supplementary Fig. 1b ), as has been reported before for XLPDR 10 .
Given the failure of prior sequencing efforts to identify a mutation in coding exons or flanking splice sites within the linkage interval, we performed whole-genome sequencing (WGS) of four unrelated probands from Canada, Australia, Italy, and Waco, Texas ( Fig. 1, red  arrows) . Within the previously identified linkage interval, we investigated both nonsynonymous protein-coding changes and non-coding variants predicted to affect mRNA splicing, searching for variants that targeted the same gene in all four probands. Due to the rarity and high penetrance of the disease, variants were excluded if present with minor allele frequency of >1% among samples from the International HapMap Project (haplotype map of the human genome) or the 1000 Genomes Project (public catalog of human variation and genotype data). Additional variants were excluded if they were present in WGS data from 18 males known not to have XLPDR whose genomes were sequenced by the same WGS method 21 . No gene in the linkage interval harbored rare nonsynonymous variants in all four patients (data not shown), in agreement with the exome-sequencing efforts noted above. However, all four probands shared the same rare A-to-G variant at position 24744696 of GenBank reference sequence NC_000023.10 for chromosome X (NC_000023.10:g.24744696A>G). This position maps to an intron of POLA1 located in the XLPDR-linkage region. POLA1 encodes the catalytic subunit of DNA polymerase-α (Polα), a DNAdirected polymerase that in vertebrates exists in a stable complex with primase. The Polα-primase complex synthesizes RNA:DNA primers, which initiate the synthesis of Okazaki fragments, and is therefore essential for DNA replication and cell proliferation [22] [23] [24] [25] .
As expected for a disease-causing mutation, the variant segregated with XLPDR or carrier status in five multiplex families tested ( Fig. 1) and was absent from 1,133 genomes from an ethnically diverse cohort (of 452 males and 681 females) 26 (Supplementary Fig. 1c ). Furthermore, DNA samples from other unrelated probands harbored the NC_000023.10:g.24744696A>G variant ( Fig. 1) . Only two subjects with the diagnosis of XLPDR were negative for this variant: a previously reported child from Lebanon 17 , and an atypical case from China who lacked the characteristic facial features of the syndrome (data not shown). Further analysis of these two subjects was not possible due to limited availability of DNA.
For further investigation of POLA1 as a candidate gene for XLPDR, we hypothesized that there would be a paucity of loss-of-function variants identified in public resequencing cohorts. In agreement with that, the Exome Aggregation Consortium of 60,706 people analyzed by next-generation sequencing reports two different predicted loss-offunction splicing variants, each in only a single heterozygous female. However, closer inspection of the predicted effects of these suggested that they might not be true loss-of-function variants (data not shown). To more robustly assess the population prevalence of potentially deleterious missense variants, we ascertained the residual variation intolerance score for POLA1 (ref. 27 ). This score measures the departure from the average number of common functional mutations found in genes with a similar mutational burden at a genome-wide level. A negative score indicates that the gene has functional variation that is less common than predicted and most often reflects purifying selection. This score for POLA1 was −0.795, which corresponds to the 12th percentile for scores genome wide. This indicates that POLA1 is under substantial purifying selection, as would be predicted for a gene encoding a product with such essential biological functions.
Given the recurrent nature of the variant among most cases of XLPDR, we performed kinship analysis 28 ; this indicated that the four subjects whose genome underwent sequencing were no closer than fifth-degree relatives. Around the shared POLA1 intronic variant, two probands (P1 and P7) shared a segment of 140 kilobases estimated to be identical by descent through the use of BEAGLE software (for the analysis of genetic data sets with markers) 29 . The other two probands (P4 and P5) did not share this segment and shared at most 3.7 kilobases in this region. Thus, while two of the families showed evidence of a distant founder effect, other cases had clearly emerged independently. Furthermore, the South Dakota proband was found to carry a de novo mutation of POLA1 ( Fig. 1) . Together our genetic data indicated that a recurrent intronic mutation in POLA1 is responsible for XLPDR.
The XLPDR mutation results in missplicing of POLA1 Next, using dermal fibroblasts derived from three probands with XLPDR ('XLPDR cells') and five control lines ('wild-type cells'), we compared the expression of genes from the XLPDR-linkage interval. Only POLA1 was substantially underexpressed in XLPDR cells ( Fig. 2a) . Furthermore, expression of POLA1 protein in XLPDR fibroblasts was markedly reduced as well ( Fig. 2b) . Analysis by immunoblot and quantitative fluorescence imaging indicated that the amount of POLA1 protein in XLPDR fibroblasts was diminished to about 35% of that seen in wild-type cells, and this was closely matched by the lower amount of mRNA observed by quantitative RT-PCR (qRT-PCR) ( Fig. 2c ). An analogous effect on the expression of mRNA and protein was noted in lymphoblastoid cell lines derived from patients with XLPDR ( Supplementary Fig. 1d-f ). Despite having reduced levels npg A r t i c l e s of POLA1, mutant fibroblasts did not display altered proliferative capacity or changes in cell-cycle distribution ( Supplementary Fig. 2a,b) . Similarly, mitogeninduced lymphocyte proliferation was unaffected in two probands in the family from Waco, Texas (Supplementary Fig. 2c ). Furthermore, silencing of POLA1 via small interfering RNA (siRNA) to a degree comparable to that seen in XLPDR did not lead to cell-cycle arrest in HeLa human cervical cancer cells, as assessed with an integrated cell-cycle reporter system ( Supplementary Fig. 2d ). Thus, the reduction in POLA1 expression in XLPDR did not seem to compromise cell replication, in agreement with the lack of an altered growth phenotype in most patients.
Next we investigated the mechanism by which the NC_000023.10: g.24744696A>G variant disrupts POLA1 gene expression. Through bioinformatics analysis 30 , we predicted that the XLPDR mutation creates a splice-donor site located 76 nucleotides downstream of a cryptic splice-acceptor sequence present in the same intron, which introduces a novel exon, 13a, into the POLA1 transcript ( Fig. 2d) . Indeed, RT-PCR confirmed the presence of an aberrant POLA1 transcript in mutant fibroblasts ( Fig. 2e) , which by sequencing included the predicted exon 13a (data not shown). Transcript-specific qRT-PCR demonstrated a 65% reduction in the abundance of wild-type mRNA in XLPDR fibroblasts relative to that in wild-type fibroblasts ( Fig. 2f) , which suggested that a substantial proportion of missplicing occurred in these cells. The misspliced mRNA was much less abundant than the correctly spliced transcript ( Fig. 2f) , which suggested that inclusion of exon 13a destabilized the transcript. Meanwhile, in lymphoblastoid cell lines derived from patients with XLPDR, the aberrant transcript could be amplified only by RT-PCR primers specific to exon 13a ( Supplementary Fig. 2e ), which suggested that it was much less abundant in these cells than in fibroblasts. To confirm that the intronic A-to-G mutation was solely responsible for the aberrant splicing, we introduced POLA1 intron 13 and its surrounding exons into an exontrapping plasmid system 31 . Intron 13 containing the XLPDR mutation led to two transcripts (Fig. 2g) , and sequencing of the larger one confirmed the presence of exon 13a (data not shown). Although the Figure 1 WGS identifies a recurrent intronic mutation as the cause of XLPDR. Pedigrees of 11 families with XLPDR, including 7 new cases, as well as probands (P1-P21) and relatives (F1-F3): place of origin is above each family pedigree; red arrows indicate probands whose DNA was analyzed by WGS; gray indicates possible cases or carriers; letters below symbols indicate POLA1 genotype (A, wild-type allele; G, XLPDR-associated allele) derived from WGS or targeted genotyping. npg A r t i c l e s aberrant exon 13a introduced a frameshift mutation, immunoblot analysis showed no evidence of a truncated protein; only reduced expression of full-length POLA1 protein was observed ( Supplementary  Fig. 2f ). Together these data indicated that the XLPDR-related mutation created a hypomorphic POLA1 allele, which ultimately reduced the expression of POLA1 protein. In addition, the data suggested that the magnitude of reduction of POLA1 expression might be subject to tissue-specific differences in missplicing.
POLA1-deficient states activate type I interferon responses
To understand how POLA1 might be linked to the XLPDR phenotype, we compared the transcriptome profiles of four control dermal fibroblast lines with those of cells derived from two unrelated patients with XLPDR (primary and telomerase-immortalized fibroblasts). Furthermore, we contrasted those findings to the effects of the silencing of POLA1 via siRNA in control fibroblasts ( Fig. 3a,b) . The primary and immortalized cells derived from patients with XLPDR displayed concordant alterations in the expression of 177 genes, compared with the expression of those genes in control fibroblasts, and nearly two thirds of those changes (102 genes) were recapitulated by silencing of POLA1 in control fibroblasts ( Fig. 3a and Supplementary Table 1 ). Most of the changes represented increased gene expression in POLA1-deficient cells (Fig. 3b) . Ontology analysis indicated that these genes encoded products involved mainly in the type I interferon signaling pathway and were regulated by members of the IRF ('interferon-regulatory factor') and NF-κB families of transcription factors (Table 1) . Therefore, we analyzed the response of mutant cells to the activation of gene expression dependent on IRFs or NF-κB following stimulation with the synthetic double-stranded DNA (dsDNA) poly(dA:dT) or the cytokine tumor-necrosis factor (TNF), respectively. In both cases, POLA1-deficient cells displayed more robust activation mainly of genes that mapped to the IRF and NF-κB pathways (Fig. 3c,d and Supplementary Table 2 ). In the case of treatment with poly(dA:dT), 35% of the gene response was affected RNA (fold)
Primary Immortalized siRNA Bioinformatics analysis of the gene alterations in Figure 3b , assessed Ingenuity Pathway Analysis focusing on shared canonical pathways and upstream regulators.
npg A r t i c l e s by POLA1 deficiency and mostly resulted in greater gene expression (137 of 387 genes; Fig. 3c ). This group included genes such as IFNA21 (which encodes interferon-α2 (IFN-α2)), several chemokine-encoding genes, genes encoding NF-κB-regulatory proteins, and multiple histone-encoding genes, which were minimally induced unless cells were POLA1 deficient ( Fig. 3c and Supplementary Table 1 ). Similar results were noted after treatment with TNF; in this condition, nearly 40% (108 of 276) of the responsive genes were affected by POLA1 deficiency (Fig. 3d) . Mutant fibroblasts were hyper-responsive not only to poly(dA:dT) and TNF but also to other forms of cytosolic dsDNA and cytosolic dsRNA, as well as to IL-1β and Toll-like receptor ligands (Supplementary Fig. 3a ). Furthermore, these alterations were mimicked by siRNA-mediated silencing of POLA1 in wild-type fibroblasts and HeLa cells ( Supplementary Fig. 3b ). Collectively, these findings indicated that reduced expression of POLA1 led to constitutive enhancement of IRF-and NF-κB-dependent gene expression, including canonical interferon-stimulated genes (ISGs) and other genes encoding pro-inflammatory factors.
XLPDR results in an interferon transcriptional signature Given that activation of a similar interferon transcriptional signature has been noted in blood cells of patients with AGS 7 , we next investigated whether transcripts of several ISGs were affected in the blood cells of patients with XLPDR. Transcripts were measured in blood from five patients (P1, P3, P7, P9 and P10) from four separate families ( Fig. 1 ) and 14 healthy 'travel' control donors, including five heterozygous carriers of the XLPDR-linked mutation. Each gene analyzed showed about tenfold higher expression in patients with XLPDR than in control subjects, a result that was significant in every case (Fig. 3e) . These findings indicated that reduced expression of POLA1 led to constitutive activation of IRF-and NF-κB-dependent genes, which resulted in a strong type I interferon response in patients with XLPDR, similar to alterations noted in AGS 9 .
The clinical phenotype of XLPDR is distinct from that of AGS In view of the molecular similarities between XLPDR and AGS, we performed a more extensive analysis of the clinical phenotype of our patient cohort, directly contrasting it to known manifestations of AGS 6 . Similar to patients with AGS, several patients reported a history of more severe manifestations during early infancy that resulted in failure to thrive (57.1%), which eventually improved spontaneously ( Supplementary Table 3 ). However, there was little overlap with the core neurological manifestations of AGS 6 , with only two subjects having a history of developmental delay (14.3%) ( Supplementary  Table 3 ). Digital vasculitis and/or necrosis (chilblains), which are common in AGS, were not reported by our patients ( Supplementary  Table 3 ). Instead, XLPDR was characterized by a unique combination of diffuse hyperpigmentation (100%), a characteristic facies (100%), recurrent lung infections (92.9%) and hypohidrosis (64.3%) ( Supplementary  Table 3 ). Additionally, these patients experienced unique Table 3 ). Autoimmune manifestations were not reported, and the patients did not have elevated titers of antinuclear antibodies or evidence of any other autoantibodies ( Supplementary Fig. 4a,b and Supplementary Table 4 ).
Increased type I interferons in patients with XLPDR
Most patients with XLPDR reported a history of recurrent bacterial infections involving the lungs and upper respiratory tract, but other invasive infections (meningitis, osteomyelitis or skin abscesses) were not reported. The organisms cultured included Streptococcus pneumoniae, Haemophilus influenza, Staphylococcus aureus, Streptococcus pyogenes and Pseudomonas aeruginosa. Two patients (14.3%) had a history of pulmonary mycobacterial infections (Mycobacterium tuberculosis and Mycobacterium avium-intracellulare), and two subjects also had a history of candidiasis ( Supplementary Table 3 ). In terms of functional analysis of the immune system, some patients displayed mild neutrophilia and lymphopenia, but the morphologic features of white blood cells, including myeloid cell ultrastructure, were normal (Supplementary Fig. 4c ). There were no changes in critical lymphoid sub-populations or the oxidative-burst capacity of neutrophils ( Supplementary Table 3 ). Immunoglobulin concentrations in the serum were largely normal, except for either an elevation in the concentration of immunoglobulin E or a reduction in this, of unclear importance ( Supplementary Table 3 ). When tested, antibody responses to vaccination antigens were also normal ( Supplementary Table 3 ).
To further investigate immunological function in XLPDR, we assessed the plasma concentrations of 38 cytokines ( Fig. 3f and Supplementary Table 5 ). The concentration of IFN-α2 was significantly elevated in these patients relative to its concentration in healthy subjects (Fig. 3f) , in agreement with the activated ISG signature noted in mRNA extracted from blood (Fig. 3e) . Moreover, the concentrations of eight additional factors were significantly elevated in these patients, including a very substantial elevation in the concentration of IL-8 ( Fig. 3f and Supplementary Table 5 ). Conversely, the concentrations of two cytokines, IFN-γ and IL-17A, were significantly lower in these patients than in healthy subjects (Fig. 3f) . Suppression of IFN-γ has been reported in patients with mutations in ISG15, who display features of AGS as well as enhanced susceptibility to mycobacterial infection 32, 33 . Similarly, defects in IL-17 signaling have been linked to pyogenic infection with S. aureus as well as chronic mucocutaneous candidiasis 34 . Collectively, the immunological phenotype of patients with XLPDR was characterized by autoinflammatory manifestations, which were probably related to chronic production of type I interferons. In addition, these patients displayed suppressed production of IL-17A, perhaps linked to their susceptibility to pyogenic infections, and reduced production of IFN-γ, which might be linked to mycobacterial infections.
POLA1 deficiency leads to activation of TBK1 and IKK Next we investigated whether signaling events that activate the IRF and NF-κB pathways were upregulated in POLA1 deficiency. In the IRF pathway, the activation of various sensors results in phosphorylation of the kinases TBK1 and IKKε, which in turn then phosphorylate members of the IRF family to promote their dimerization and translocation to the nucleus 35 . Fibroblasts from patients with XLPDR displayed robust phosphorylation of TBK1, even in baseline conditions, that far exceeded the signature noted for wild-type cells (Fig. 4a) . Similarly, silencing of POLA1 in HeLa cells led to phosphorylation of both TBK1 and IKKε that exceeded the phosphorylation achieved A r t i c l e s in control cells after stimulation with poly(dA:dT) (Fig. 4b) .
This signature was accompanied by enhanced phosphorylation of IRF3 in nuclear fractions (Fig. 4b) . We found that after stimulation with TNF, XLPDR fibroblasts achieved a degree of degradation of the NF-κB inhibitor IκBα and nuclear accumulation of NF-κB (the RelA subunit) similar to that of wild-type cells ( Fig. 4c and Supplementary  Fig. 5a,b) . However, in both fibroblasts and HeLa cells, POLA1 deficiency was associated with greater phosphorylation of RelA (Fig. 4c,d) , a result we also assessed by quantitative fluorescence imaging (Supplementary Fig. 5c ). This event is mediated by the IKK complex and can increase transcriptional induction 36 . In agreement with that finding, the phosphorylated and active forms of IKK1 and IKK2 were increased in XLPDR fibroblasts as well as in HeLa cells after siRNA-mediated silencing of POLA1 (Fig. 4e) . Thus, these data showed that POLA1 deficiency led to the activation of signaling cascades that converged on TBK1, IKKε and the IKK complex. Blockade of TBK1 with a specific kinase inhibitor was sufficient to reverse the increased ISG expression ( Fig. 4f) , which indicated that the activation of this kinase in XLPDR cells was necessary for the activation of IRFs and their downstream gene targets. Together these data indicated that POLA1 deficiency resulted in augmented signals that converged on key kinases that activate IRF and NF-κB.
POLA1 deficiency leads to diminished cytosolic RNA:DNA hybrids To elucidate the constitutive activation of the IRF pathway in XLPDR, we investigated whether increased amounts of cytosolic nucleic acids could be a possible trigger for this. To this end, we used antibodies with defined reactivity to specific nucleic acids to immunoprecipitate these molecules from cytosolic fractions and stained the material recovered with a dye (PicoGreen) specific for double-stranded nucleic acid (Fig. 5a) . The cytosolic dsDNA content of XLPDR fibroblasts was slightly lower than that of control cells, whereas cytosolic RNA:DNA was almost undetectable in XLPDR fibroblasts (Fig. 5b) . The decrease in cytosolic RNA:DNA observed in XLPDR fibroblasts was also seen after silencing of POLA1 in human embryonic kidney 293T cells (HEK293T cells) and HeLa cells ( Fig. 5c and Supplementary Fig. 6a,b) . We then investigated whether the reduction in cytosolic RNA:DNA content in XLPDR fibroblasts could be 'rescued' by re-expression of POLA1. Lentiviral transduction of POLA1 into these cells led to increased cytosolic RNA:DNA (Fig. 5d) . This 'rescue' was accompanied by a substantial reduction in the amount of phosphorylated TBK1 (Fig. 5e) and normalization of the poly(dA:dT)-dependent induction of the ISG IFIT1 (Fig. 5f) . Thus, POLA1 deficiency led to decreased levels of cytosolic RNA:DNA, which correlated directly with the XLPDR cellular phenotype. npg A r t i c l e s POLA1 polymerase activity sustains cytosolic RNA:DNA levels As mentioned above, the role of the Polα-primase complex during DNA replication is to synthesize an RNA:DNA primer on a DNA template strand 22 , which would suggest a possible direct link between the polymerase activity of POLA1 and the synthesis of cytosolic RNA:DNA. To investigate this hypothesis, we first assessed the subcellular localization of POLA1 and found that a substantial proportion of POLA1 localized to the cytosol, as determined by both immunofluorescence staining and biochemical fractionation (Supplementary Fig. 7a,b) . Moreover, cytosolic POLA1 colocalized with RNA:DNA with a speckled pattern ( Supplementary  Fig. 7c ). Indeed, cytosolic POLA1 (but not other DNA-binding proteins tested) co-immunoprecipitated with nucleic acids, as determined by staining of beads with PicoGreen (Fig. 6a) . This material was sensitive to treatment with either DNase or RNase (Fig. 6b) , and, after elution from POLA1, this material was re-immunoprecipitated in part by the antibody to RNA:DNA (Fig. 6c) . The eluted nucleic acids could be resolved by on-chip capillary electrophoresis and by agarose-gel electrophoresis and consisted predominantly of fragments 40-100 base pairs (bp) in size ( Fig. 6d,e) . Thus, cytosolic POLA1 associated with short nucleic acids that included, at least in part, RNA:DNA.
Next we investigated whether the polymerase activity of POLA1 was involved in the generation of cytosolic RNA:DNA. Cytosolic levels of RNA:DNA, which by immunoprecipitation and bead staining were diminished by silencing of POLA1, were 'rescued' by re-expression of wild-type POLA1; however, a polymerase-deficient form of POLA1 did not 'rescue' the levels of cytosolic RNA:DNA and in fact had a dominant-negative effect ( Fig. 6f and  Supplementary Fig. 8 ). In aggregate, these studies indicated that POLA1, through its polymerase activity, was responsible for a substantial proportion of the physiological concentration of cytosolic RNA:DNA hybrids.
Cytosolic RNA:DNA downregulates antiviral gene expression Next we investigated whether the generation of cytosolic RNA:DNA might be directly responsible for the modulation of IRF activation. First, we isolated cytosolic RNA:DNA through immunoprecipitation and nucleic acid purification; we then transfected this material into cells in which POLA1 had been silenced. The transfection of cytosolic RNA:DNA normalized the increased expression of IRF target genes that resulted from POLA1 deficiency (Fig. 6g) . We then investigated whether synthetic nucleic acids were able to recapitulate the effects of native cytosolic RNA:DNA. We made synthetic RNA:DNA duplexes consisting of 30 bp of DNA annealed to an RNA:DNA strand (consisting of 10 bp of RNA and 20 bp of DNA), meant to mimic the RNA: DNA primer synthesized by the Polα-primase complex during DNA replication. Transfection of this material indicated that RNA:DNA duplexes of this type were able to suppress the abnormal activation of IRF target genes observed as a result of POLA1 deficiency (Fig. 6h) . Thus, endogenous and synthetic RNA:DNA hybrids were able to directly 'rescue' the effects of POLA1 deficiency, at least in the context of select ISG expression.
Cytosolic RNA:DNA modulates nucleic acid-sensor pathways Finally, we investigated whether the effects of cytosolic RNA:DNA hybrids could be mapped to a specific nucleic acid-sensor pathway upstream of TBK1. To explore this question, we used primary mouse embryo fibroblasts with defects in genes encoding key factors involved in the sensing of nucleic acid: Myd88 -/-Ticam1 -/cells (with double deficiency in the adaptors Myd88 and TRIF), Tmem173 -/cells (deficient in the membrane-associated adaptor Sting), Mb21d1 -/cells (called 'Cgas -/-' here; deficient in the DNA sensor cGAS) and Mavs -/cells (deficient in the signaling adaptor MAVS). By analysis of these cells, we found that Cgas -/and Mavs -/fibroblasts were particularly resistant to the effects of Pola1-specific siRNA (Fig. 7) . The loss of other sensor pathways also partially 'rescued' the phenotype associated with POLA1 deficiency. These findings suggested that cytosolic RNA:DNA 'preferentially' regulated pathways upstream of MAVS and cGAS and might potentially have broader effects on other sensors of nucleic acids.
DISCUSSION
This study has demonstrated that XLPDR is caused by a recurrent intronic mutation that results in missplicing and reduced POLA1 expression. This mutation previously escaped detection because it lies deep within an intron, which highlights the utility of WGS for elucidating the genetic basis of rare diseases. The finding that a unique POLA1 mutation causes XLPDR is notable. The recurrent nature of the mutation might indicate that this genomic position is a mutational 'hot spot' . In considering this possibility, it is important to note that this mutation might result in tissue-specific effects on missplicing and variable effects on POLA1 expression. If this were the case, other mutations that cause ubiquitous POLA1 deficiency would probably result in phenotypes such as AGS, a possibility that will require additional investigation. Therefore, it is possible that phenotypic ascertainment and not mutational frequency might be responsible for our finding of only one mutation associated with XLPDR. The possibility that the XLPDR-related mutation results in a gain-of-function effect cannot be completely excluded but seems very unlikely, since we did not detect any aberrant protein but instead observed perfectly concordant cellular phenotypes of the XLPDR-related mutation and siRNA-mediated silencing of POLA1. Moreover, re-expression of POLA1 in XLPDR cells 'rescued' all aberrant aspects of their cellular phenotype, in agreement with our interpretation that the mutation identified here results in loss of function.
Our study has also provided detailed characterization of this syndrome, including a careful evaluation of the immunological phenotypes of these patients. In our study, XLPDR had the molecular signature of an 'interferonopathy' and was associated with suppression of IL-17A and IFN-γ, changes probably linked to the patients' history of autoinflammation and recurrent infections. Notably, suppression of A r t i c l e s IL-17A has been previously linked to the activation of IRFs 37 . While these molecular features are similar to those of AGS, most of the clinical features of XLPDR we found were distinct, including the paucity of neurological involvement that is central to the presentation of most cases of AGS. In addition, the development of hyperpigmentation, hypohidrosis and facial features in XLPDR remain unexplained from a mechanistic standpoint. We anticipate that as additional cases are identified, new insights into the pathogenesis of this disorder will be gained. The role of POLA1 in the synthesis of cytosolic RNA:DNA was unexpected, given the current knowledge of the Polα-primase complex. We predict that this complex mediates the same biochemical steps in the biosynthesis of cytosolic nucleic acids as those defined during DNA replication; thus, template DNA is the likely substrate for the synthesis of cytosolic RNA:DNA, and the source of this DNA will need to be ascertained. This nonreplicative function for POLA1 is in agreement with its abundant cytosolic localization in many cell types and its persistent expression in postmitotic cells 38, 39 .
Similarly, the finding of a role for cytosolic RNA:DNA in preventing spontaneous activation of the IRF pathway was also unexpected. These data stand in contrast with published reports that synthetic RNA:DNA duplexes can have stimulatory effects. It is therefore important to note key differences in our approach versus those of published studies 40 . First, to our knowledge, this is the first study to test the effect of native RNA:DNA extracted directly from the cytosol. This material captures the heterogeneity of chemistry and nucleotide length that is probably present in vivo, including possible hybrid duplexes (DNA annealed to RNA) or hybrid strands (ribonucleotides and deoxynucleotides linked together) or a combination of these. Thus, our experiment avoided the use of RNA:DNA chemistries of unclear physiological relevance, such as long synthetic palindromic RNA:DNA duplexes (>1 kilobase), which according to our analysis do not represent the predominant composition of cytosolic RNA:DNA. In addition, for studies of synthetic nucleotides, we used RNA:DNA consisting of a short duplex DNA strand annealed to a hybrid RNA:DNA strand, meant to recapitulate the product synthesized by Polαprimase during DNA replication. In aggregate, our results suggest a mechanistic model whereby RNA:DNA hybrids synthesized by cytosolic POLA1 act to squelch the responses generated by stimulatory nucleic acids. One possible mechanism for this might be that cytosolic RNA:DNA could bind to nucleic acid sensors without triggering their activation and could compete with their cognate ligands and thus set a higher threshold for the generation of signals. Given the genetic evidence presented here, cytosolic RNA: DNA might in fact modulate multiple sensors. Finally, the finding that a partial reduction in the expression of POLA1 altered immunological regulation without blocking DNA replication would suggest that Polα might provide a new target for the therapeutic modulation of innate immunity.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: RNA-seq data, GSE72589.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. gene subsets created from the list of significant genes. Functional analysis of identified genes was performed with Ingenuity Pathway Analysis (IPA; Ingenuity Systems, Redwood City, CA; http://www.ingenuity.com).
Cell-proliferation analyses. For DNA content analysis, ~1 × 10 6 cells were resuspended in PBS, and fixed in cold 70% ethanol for 30 min at 4 °C. Fixed fibroblasts were washed twice with PBS and treated 15 min at RT with RNase A (5 µg/ml, Qiagen), with subsequent staining with propidium iodide (500 ng/ ml, Sigma-Aldrich). Cells were analyzed by flow cytometry using FACSCalibur (BD Biosciences) and FlowJo software. Fluorescence ubiquitination-based cell cycle indicator (FUCCI) HeLa cells were similarly analyzed by flow cytometry using the EGFP and DsRed indicator proteins. Mitogen stimulation of lymphocytes was performed by the Diagnostic Immunology Laboratory at Cincinnati Children's Hospital as part of medical care due to the history of recurrent infections.
Immunofluorescence staining. Cells were growing in Nunc Lab-Tek Chamber slides (Thermo) for 48 h. Cells were fixed in ice-cold 100% methanol for 15 min, and washed three times with PBS. Blocking buffer was applied (5% human serum, 1% glycerol, 0.1% BSA, 0.1% fish skin gelatin, 0.04% sodium azide, in PBS, pH 7.2). If required, selected samples were incubated with 0.25 µg/µl RNase A (Invitrogen) at 37 °C for 30 min. Samples were incubated in a humidifier chamber overnight at 4 °C with primary antibodies diluted in blocking buffer (POLA1, polyclonal, Santa Cruz, sc-5921, dilution 1:50; RNA:DNA, clone S9.6, Kerafast, ENH001, dilution 1:50; RelA, polyclonal, Santa Cruz, sc-372, dilution 1:500). Following three washes in PBS, cells were incubated with secondary antibodies with the dilution 1:500 in blocking buffer (Alexa Fluor 568 donkey anti-rabbit (Life Technologies, A10042), Alexa Fluor 594 chicken anti-mouse (Life Technologies, A21201) and Alexa 647 donkey anti-goat (Life Technologies, A21450)) for 1 h at room temperature in a humidifier chamber. After four washes in PBS and the addition of Hoechst 33342 nuclear stain, coverslips were rinsed in water and affixed to slides with Slowfade Antifade reagent (Invitrogen). Images were obtained with an LSM-710 laser scanning confocal microscope with a 60×/1.4 Oil Plan-Aprochromat objective lens using ZEN software (Carl Zeiss).
TBK1 inhibition.
Mouse fibroblasts were transfected with siRNA targeting Pola1 or control sequence. After 48 h, the cells were washed with PBS, and fresh medium was applied containing 10 µM BX795 (Sigma) or vehicle (DMSO) as control. After 6 h, the cells were washed with PBS, and RNA was extracted using Trizol (Sigma).
Plasma cytokine multiplex analysis. Blood samples from patients with XLPDR and healthy controls were obtained in duplicate by local hospitals. EDTA-plasma was separated from blood samples by centrifugation and stored at −80 °C. Samples were analyzed with Human Cytokine/Chemokine Magnetic Bead Panel (Milliplex, HCYTMAG-60K-PX38, Millipore) on Luminex Magpix with the Luminex xPONENT software according to manufacturer's instructions. Data analysis was done using Milliplex Analyst. ANA ELISA. ELISA was used to screen for presence of antinuclear antibodies (ANA) (Inova Diagnostics Inc., San Diego, CA). About 5 µl of human serum was used for each reaction in a dilution of 1:41. ANA ELISA detects antibodies to various nuclear antigens, such as chromatin, Sm/RNP, SS-A, SS-B. Scl-70, centromere, PCNA, Jo-1 and ribosomal proteins. The assay was performed and results were interpreted as per manufacturer's instructions. The manufacturer's definition of positivity for ANA is greater than 20 units.
Autoantigen array. Autoantigen microarrays were manufactured, hybridizated and scanned as previously described 49 . Antigens were diluted to printing concentration in printing buffer (Whatman, Sanford, ME, USA) and transferred to 384-well plates. The antigens were printed in duplicate onto nitrocellulose-coated 16-pad FASTTM slides (Whatman, Sanford, ME, USA) by MicroGrid II 610 bio-robotics array printer (Genomic Solutions Inc., Ann Arbor, MI, USA). After printing, the slides were kept in a chamber with 70% humidity for 4 h at room temperature, and stored at 4 °C. For hybridization,
